Abivax to present at multiple fall investor conferences in Nov-Dec 2026

Abivax, a clinical-stage biotech company focused on immune regulation therapies, announced its participation in several upcoming investor conferences this fall, including events in Boston, London, Frankfurt, Miami, and New York. These presentations and fireside chats will highlight Abivax's progress, particularly around its lead drug candidate obefazimod, which is in Phase 3 trials for ulcerative colitis. Webcasts of select presentations will be available on Abivax's investor website. This engagement aims to update investors on clinical developments and company strategy.

As of Nov 03, 2026 04:26 WIB, Abivax SA American Depositary Shares (ABVX) trade at USD 84.84 on Pluang, down 2.04% in the past day. The stock shows a market cap of $7.74 billion and a trading volume of 843,412 shares. This price movement occurs as Abivax prepares for multiple investor conferences this fall.